We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
NEJM发表了基因疗法VERVE-102的1b期结果：单次注射后LDL降低62%。分析其疗效、风险及对高胆固醇血症患者的前景。了解更多。
